ATC Group: G04B Other urologicals, incl. antispasmodics

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G04B in the ATC hierarchy

Level Code Title
1 G Genito urinary system and sex hormones
2 G04 Urologicals
3 G04B Other urologicals, incl. antispasmodics

Group G04B contents

Code Title
G04BA Acidifiers
G04BC Urinary concrement solvents
G04BD Urinary antispasmodics
G04BE Drugs used in erectile dysfunction
G04BX Other urologicals

Active ingredients in G04B

Active Ingredient Description
Acetohydroxamic acid

Acetohydroxamic acid (AHA) is a stable, synthetic compound derived from hydroxylamine and ethyl acetate. Its molecular structure is similar to urea. AHA reversibly inhibits the bacterial enzyme urease, thereby inhibiting the hydrolysis of urea and production of ammonia in urine infected with urea-splitting organisms. The reduced ammonia levels and decreased pH enhance the effectiveness of antimicrobial agents and allow an increased cure rate of these infections.

Alprostadil

Alprostadil is chemically identical to prostaglandin E1, the actions of which include vasodilatation of blood vessels in the erectile tissues of the corpora cavernosa and increase in cavernosal artery blood flow, causing penile rigidity.

Ammonium chloride
Apomorphine

Apomorphine is a direct stimulant of dopamine receptors and while possessing both D1 and D2 receptor agonist properties does not share transport or metabolic pathways with levodopa. Its actions on parkinsonian motor disability are likely to be mediated at post-synaptic receptor sites.

Avanafil

Avanafil is a highly selective and potent, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5. When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by avanafil produces increased levels of cGMP in the corpus cavernosum of the penis. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection.

Calcium chloride

Calcium is the most abundant mineral in the body, and is an essential body electrolyte. Homeostasis is mainly regulated by the parathyroid hormone, by calcitonin, and by the activated form of vitamin D. Calcium is a structural component of bones and teeth. It is also required for blood clotting, neurotransmitter release, muscle contraction and normal heartbeat.

Collagen
Dapoxetine

Dapoxetine is a potent selective serotonin reuptake inhibitor (SSRI). The mechanism of action of dapoxetine in premature ejaculation is presumed to be linked to the inhibition of neuronal reuptake of serotonin and the subsequent potentiation of the neurotransmitter’s action at pre- and postsynaptic receptors.

Darifenacin

Darifenacin is a selective muscarinic M3 receptor antagonist (M3 SRA) in vitro. The M3 receptor is the major subtype that controls urinary bladder muscle contraction. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.

Desfesoterodine

Desfesoterodine is a competitive, specific muscarinic receptor antagonist. It is the primary active metabolite of fesoterodine, and regarded as main active pharmacological principle of fesoterodine; fesoterodine is considered as prodrug of desfesoterodine. The affinity of desfesoterodine for the muscarinic receptors is 2 orders of magnitude greater than that of fesoterodine.

Dimethyl sulfoxide

Dimethyl sulfoxide is used for the symptomatic relief of patients with interstitial cystitis. There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial infections of the urinary tract.

Fesoterodine

Fesoterodine is a competitive, specific muscarinic receptor antagonist. It is rapidly and extensively hydrolysed by non-specific plasma esterases to the 5-hydroxymethyl derivative, its primary active metabolite, which is the main active pharmacological principle of fesoterodine.

Flavoxate

Flavoxate is an antispasmodic selective to the urinary tract. Flavoxate has been shown to have a direct antispasmodic action on smooth muscle fibres.

Imidafenacin

Imidafenacin is an antagonist of muscarinic cholinergic receptors and used for treatments of overactive bladder. Imidafenacin antagonizes subtypes M3 and M1 in vitro. In the urinary bladder, imidafenacin inhibits acetylcholine release by antagonizing subtype M1 and contraction of smooth muscles by antagonizing subtype M3. Compared with the inhibitory effect on the salivary gland, imidafenacin shows higher inhibitory effect on the urinary bladder contraction, probably indicating efficacy and safety of these products in the clinical practice.

Magnesium hydroxide

Magnesium hydroxide is practically insoluble in water and solution is not effected until the hydroxide reacts with hydrochloric acid in the stomach to form magnesium chloride. Its neutralising action is almost equal to that of sodium bicarbonate. When the dose is in excess of that required to neutralise the acid the intragastric pH may reach pH 8 or 9. Acid rebound following magnesium hydroxide is clinically insignificant. Magnesium hydroxide has an indirect cathartic effect resulting from water retention in the intestinal lumen.

Mirabegron

Mirabegron is a potent and selective beta3-adrenoceptor agonist. Mirabegron enhances urine storage function by stimulating beta3-adrenoceptors in the bladder.

Oxybutinin

Oxybutynin acts as a competitive antagonist of acetylcholine at post-ganglionic muscarinic receptors, resulting in relaxation of bladder smooth muscle.

Papaverine
Pentosan polysulfate

The hypothetic mechanism of action of pentosan polysulfate includes a local effect in the bladder after systemic administration and excretion into the urine by binding of glycosaminoglycans to the deficient mucous of the bladder. It is hypothesized, that a potential barrier function of pentosan polysulfate instead of the damaged urothelial mucus might play a role as well the antiinflammatory activity of pentosan polysulfate sodium.

Phenazopyridine

Phenazopyridine is excreted in the urine where it exerts a topical analgesic effect on the mucosa of the lower urinary tract. This action helps to relieve pain, burning, urgency and frequency. The precise mechanism of action is unknown.

Propiverine

Propiverine inhibits calcium influx and modulates intracellular calcium in urinary bladder smooth muscle cells causing musculotropic spasmolysis. Also, it inhibits the efferent connection of the nervus pelvicus due to anticholinergic action.

Sildenafil

Sildenafil is a potent and selective inhibitor of cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5), the enzyme that is responsible for degradation of cGMP. Apart from the presence of this enzyme in the corpus cavernosum of the penis, PDE5 is also present in the pulmonary vasculature. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation.

Solifenacin

Solifenacin is a competitive, specific cholinergic-receptor antagonist. In vitro and in vivo pharmacological studies indicate that solifenacin is a competitive inhibitor of the muscarinic M3 subtype receptor.

Tadalafil

Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). When sexual stimulation causes the local release of nitric oxide, inhibition of PDE5 by tadalafil produces increased levels of cGMP in the corpus cavernosum. This results in smooth muscle relaxation and inflow of blood into the penile tissues, thereby producing an erection. The effect of PDE5 inhibition on cGMP concentration in the corpus cavernosum is also observed in the smooth muscle of the prostate, the bladder and their vascular supply. The resulting vascular relaxation increases blood perfusion which may be the mechanism by which symptoms of benign prostatic hyperplasia are reduced.

Terodiline
Tiopronin

Tiopronin is similar to penicillamine in both chemistry and pharmacology and used to control the rate of cystine precipitation and excretion in the disease cystinuria. The drug works by reacting with urinary cysteine to form a more soluble, disulfide linked, tiopronin-cysteine complex

Tolterodine

Tolterodine is a competitive, specific muscarinic receptor antagonist with selectivity for the urinary bladder over salivary glands in vivo.

Trospium

Trospium is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Receptor assays showed that trospium has negligible affinity for nicotinic receptors as compared to muscarinic receptors at concentrations obtained from therapeutic doses. Trospium antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder.

Udenafil

Udenafil, an oral therapy for the treatment of erectile dysfunction (ED), is a pyrazolopyrimidinone class and a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) of the corpus cavernosum, which induce potent penile erection.

Vardenafil

Vardenafil is a potent and selective inhibitor of the cGMP specific phosphodiesterase type 5 (PDE5), the most prominent PDE in the human corpus cavernosum. Vardenafil is an oral therapy for the improvement of erectile function in men with erectile dysfunction. In the natural setting, i.e. with sexual stimulation it restores impaired erectile function by increasing blood flow to the penis.

Vibegron

Vibegron is a selective human beta-3 adrenergic receptor agonist. Activation of the beta-3 adrenergic receptor increases bladder capacity by relaxing the detrusor smooth muscle during bladder filling.

Yohimbine

Related product monographs

Title Information Source Document Type  
BETMIGA Prolonged-release tablet European Medicines Agency (EU) MPI, EU: SmPC
BLADURIL Film-coated tablet Health Products Regulatory Authority (ZA) MPI, Generic
CAVERJECT Powder for solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
CIALIS 2.5 mg Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
CIALIS 5 mg Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
DETROL LA Capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
DETRUNORM Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
EDEX Powder for solution FDA, National Drug Code (US) MPI, US: SPL/Old
ELMIRON Hard capsule European Medicines Agency (EU) MPI, EU: SmPC
EMSELEX Prolonged-release tablet European Medicines Agency (EU) MPI, EU: SmPC
ENABLEX Extended-release tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
GEMTESA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
GRANPIDAM Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
KENTERA Transdermal patch European Medicines Agency (EU) MPI, EU: SmPC
LEVITRA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
LITHOSTAT Tablet FDA, National Drug Code (US) MPI, US: SPL/Old
LYRINEL XL Prolonged release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MUSE Urethral Stick Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
MYSILDECARD Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
OXYTROL Transdermal system FDA, National Drug Code (US) MPI, US: SPL/PLR
PRILIGY Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PROSTIN E2 Concentrate for solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PROSTIN E2 Vaginal tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
PYRIDIUM Tablet Health Products and Food Branch (CA) MPI, CA: SPM
QUATOR Film-coated tablet Health Products Regulatory Authority (IE) MPI, EU: SmPC
REGURIN XL Prolonged-release capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
REVATIO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
REVATIO Solution for injection European Medicines Agency (EU) MPI, EU: SmPC
SPEDRA Tablet European Medicines Agency (EU) MPI, EU: SmPC
STAXYN Tablet, orally disintegrating FDA, National Drug Code (US) MPI, US: SPL/PLR
STENDRA Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
TADALAFIL MYLAN Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
TALMANCO Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
TOLTERODINE ACCORD Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TOVEDESO Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
TOVIAZ Prolonged-release tablet European Medicines Agency (EU) MPI, EU: SmPC
TRIPAN 20mg Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
TRIPAN 5mg Film-coated tablet Υπουργείο Υγείας (CY) MPI, EU: SmPC
URAPLEX Coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
URISPAS Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
URITOS / URITOS OD Tablet Web Search MPI, US: SPL/Old
VESICARE Oral suspension Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VEZIMED Film-coated tablet Web Search MPI, EU: SmPC
VIAGRA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
VIAGRA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
VIVANZA Film-coated tablet European Medicines Agency (EU) MPI, EU: SmPC
ZYDENA Tablet Web Search MPI, Generic